1-甲基-3-三氟甲基-4-溴-1H-吡唑 | 497832-99-2

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 1-甲基-3-三氟甲基-4-溴-1H-吡唑
• 中文别名: 1-甲基-3-三氟甲基-4-溴吡唑；4-溴-1-甲基-3-三氟甲基吡唑
• 英文名称: 4-bromo-1-methyl-3-(trifluoromethyl)-1H-pyrazole
• 英文别名: 4-bromo-1-methyl-3-(trifluoromethyl)pyrazole
• CAS: 497832-99-2
• 化学式: C₅H₄BrF₃N₂
• 分子量: 228.999
• InChiKey: TZAYNGPUOOUEAP-UHFFFAOYSA-N

物化性质

• 沸点：
  52 °C
• 密度：
  1.82±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	4-Bromo-1-methyl-3-(trifluoromethyl)-1H-pyrazole Material Safety Data Sheet
Synonym:	None Known
CAS:	497832-99-2

Section 1 - Chemical Product MSDS Name:4-Bromo-1-methyl-3-(trifluoromethyl)-1H-pyrazole Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
497832-99-2	4-Bromo-1-methyl-3-(trifluoromethyl)-1	97+	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation. Vacuum or sweep up material and place into a suitable, dry disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 497832-99-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid or liquid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 52-56 deg C @ 0.5mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H4N2F3Br
Molecular Weight: 231.92

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions. Low melting point solid.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen fluoride gas, hydrogen bromide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 497832-99-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-1-methyl-3-(trifluoromethyl)-1H-pyrazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 6 Keep under nitrogen.
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 497832-99-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 497832-99-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 497832-99-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-3-三氟甲基-4-溴-1H-吡唑 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 caesium carbonate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 0.75h， 生成 3-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-N-(m-tolyl)benzamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of pyrazole-aromatic containing carboxamides as potent SDH inhibitors

  摘要：

  DOI：

  10.1016/j.ejmech.2021.113230
• 作为产物：
  描述：

  1-甲基-3-三氟甲基-1H-吡唑 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 以92%的产率得到1-甲基-3-三氟甲基-4-溴-1H-吡唑
  参考文献：
  名称：

  官能化的1-甲基-3 / 5-（三氟甲基）-1 H-吡唑的实用合成方法

  摘要：

  一种新的，高产且实用的合成1-甲基-3-（三氟甲基）-1H-吡唑和1-甲基-5-（三氟甲基）-1H-吡唑的重要实用方法到药物和农业化学的发展。从4-乙氧基-1,1,1-三氟-3-丁烯-2-一开始，提出了一步合成目标吡唑区域异构混合物的步骤。此混合物的分离步骤，阐述了沸点的基础上VS压力图分析。证明了在第3和第5位带有CF 3基团的区域异构结构单元的有效合成策略。一组1-甲基-3-（三氟甲基）-1 H基于1-甲基-3-（三氟甲基）-1 H-吡唑的锂化反应，合成了含有醛，酸，松果酸硼酸，亚磺酸锂和磺酰氯等官能团的β-吡唑。NBS在温和的条件下对1-甲基-3-（三氟甲基）-1 H-吡唑和1-甲基-5-（三氟甲基）-1 H-吡唑进行溴化。在1-甲基-5-（三氟甲基）-1 H的4位上引入官能团通过在适当的溴化物中进行Br-Li交换，优化了相应的醛和酸的合成，说明了吡唑。或者，基于4-溴的直接原位金属

  DOI：

  10.1021/acs.oprd.0c00300

文献信息

• [EN] COMT INHIBITORS<br/>[FR] INHIBITEURS DE COMT
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014102233A1

  公开（公告）日：2014-07-03

  The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.

  本发明涉及式(I)的化合物，其中取代基如权利要求1所述，并且其药学上可接受的盐。这些化合物抑制酶儿茶酚-O-甲基转移酶(COMT)。这些化合物可用于治疗帕金森病、抑郁症、认知障碍和运动症状、抗抑郁症、认知障碍、情绪和精神分裂症的消极症状。
• [EN] AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS<br/>[FR] DÉRIVÉS D'AZABICYCLO[3.1.0]HEXYLE EN TANT QUE MODULATEURS DE RÉCEPTEURS DOPAMINERGIQUES D3
  申请人：GLAXO GROUP LTD

  公开号：WO2009043883A1

  公开（公告）日：2009-04-09

  The present invention relates to novel compounds of formula (I) or a salt thereof: wherein R1 is a 5-membered heteroaryl group, optionally fused with a 6-membered hetero or carbocycle; such 5 or 11-membered system, may be optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl, haloC1-4alkoxy and SF5, and n is 1 or 2; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.

  本发明涉及式(I)的新化合物或其盐：其中R1是一个5-成员杂芳基团，可选地与一个6-成员杂环或碳环融合；这样的5或11-成员体系，可以选择地由卤素、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4烷酰基、卤代C1-4烷氧基和SF5中的1、2、3或4个取代基取代，并且n为1或2；其制备方法，用于这些方法的中间体，含有它们的药物组合物以及它们在治疗中的用途，作为多巴胺D3受体调节剂，例如用于治疗药物依赖、作为抗精神病药物、用于治疗强迫症谱系障碍或早泄。
• Fused Bicyclic Kinase Inhibitors
  申请人：Mulvihill Mark J.

  公开号：US20110281888A1

  公开（公告）日：2011-11-17

  Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

  公式I的化合物如下所示并在此定义： 其药用可接受盐、合成、中间体、配方以及使用其进行疾病治疗的方法，包括治疗癌症，如至少部分由RON、MET或ALK驱动的肿瘤。本摘要不限制该发明。
• 4-Methylsulfonyl-Substituted Piperidine Urea Compounds
  申请人：MyoKardia, Inc.

  公开号：US20160243100A1

  公开（公告）日：2016-08-25

  The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.

  本发明提供了一种新颖的4-甲基砜取代哌啶脲化合物，可用于治疗扩张型心肌病（DCM）以及与左心室和/或右心室收缩功能障碍或收缩储备相关的疾病。描述了这些化合物的合成和表征，以及治疗DCM和其他形式心脏疾病的方法。
• Intermolecular Palladium(0)-Catalyzed Atropo-enantioselective C–H Arylation of Heteroarenes
  作者：Qui-Hien Nguyen、Shu-Min Guo、Titouan Royal、Olivier Baudoin、Nicolai Cramer

  DOI：10.1021/jacs.9b12299

  日期：2020.2.5

  rare and challenging. An intermolecular and highly enantioselective C-H arylation of relevant heteroarenes providing an efficient access to atropisomeric (hetero)biaryls is reported. The use of a Pd(0) complex equipped with H8-BINAPO as chiral ligand enables the direct functionalization of a broad range of 1,2,3-triazoles and pyrazoles in excellent yields and selectivities of up to 97.5:2.5 er. The

  阻转异构（杂）联芳基是在配体、天然产物和生物活性分子中越来越重要的基序。通过有效的 CH 功能化方法直接构建立体轴非常罕见且具有挑战性。据报道，相关杂芳烃的分子间和高度对映选择性 CH 芳基化提供了对阻转异构（杂）二芳基的有效途径。使用配备有 H8-BINAPO 作为手性配体的 Pd(0) 配合物能够以高达 97.5:2.5 er 的优异产率和选择性直接官能化范围广泛的 1,2,3-三唑和吡唑。该方法还允许 atroposelective 双 CH 芳基化，用于构建两个具有 >99.5:0.5 er 的立体轴。